[Efficacy of sacituzumab govitecan in multi-treated metastatic breast cancer and clinical management of oligoprogressions.].

The case described concerns a 54-year-old woman diagnosed with triple-negative breast cancer, which initially presented with metastatic disease in the breast, axillary lymph nodes, skin, and liver. The diagnostic and therapeutic process lasted over eight years and alternated the use of standard therapy based on available scientific evidence and local treatments for oligoprogression, ensuring the patient a long survival with a good quality of life, up to the point of being able to use sacituzumab govitecan, which she received for 28 cycles. The case is completed by genetic and molecular NGS profiling and explores the possibility of continuing treatment with sacituzumab govitecan in case of oligoprogression.